Joshua Wilcox, Benedict Mcdonaugh, Rea Ganatra, Alexander Birkinshaw, Vitaliy Androshchuk, Omar Chehab, Ioannis Lianos, Edouard Long, Satpal Arri, Karine Grigoryan, Giulia Benedetti, Rebecca Preston, Bushra Rana, Christopher Aldo Rinaldi, Ronak Rajani, Pier Giorgio Masci, Simon Redwood, Bernard Prendergast
{"title":"State of the art: Transcatheter tricuspid valve intervention.","authors":"Joshua Wilcox, Benedict Mcdonaugh, Rea Ganatra, Alexander Birkinshaw, Vitaliy Androshchuk, Omar Chehab, Ioannis Lianos, Edouard Long, Satpal Arri, Karine Grigoryan, Giulia Benedetti, Rebecca Preston, Bushra Rana, Christopher Aldo Rinaldi, Ronak Rajani, Pier Giorgio Masci, Simon Redwood, Bernard Prendergast","doi":"10.1177/20480040261467513","DOIUrl":null,"url":null,"abstract":"<p><p>Tricuspid regurgitation (TR) has a community prevalence of 3%, which increases with age and affects up to 7% of elderly patients. TR is secondary (functional) in 90% of cases (usually resulting from left heart disease and/or pulmonary hypertension), although atrial dilatation is an increasingly recognised cause. Awareness of the poor prognosis associated with increasing TR severity has refocused the quest for effective treatments. Surgical intervention has been hindered by high in-hospital mortality (up to 10%), even in carefully selected cases, and transcatheter tricuspid valve interventions (TTVIs) have emerged as a low-risk alternative for this high-risk cohort. Increasing data demonstrate the clinical safety and efficacy of TTVIs, but uncertainties remain concerning optimal case selection and procedural timing. Herein, we review newly established techniques alongside emerging clinical and procedural outcome data.</p>","PeriodicalId":30457,"journal":{"name":"JRSM Cardiovascular Disease","volume":"15 ","pages":"20480040261467513"},"PeriodicalIF":0.6000,"publicationDate":"2026-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13424762/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JRSM Cardiovascular Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/20480040261467513","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Tricuspid regurgitation (TR) has a community prevalence of 3%, which increases with age and affects up to 7% of elderly patients. TR is secondary (functional) in 90% of cases (usually resulting from left heart disease and/or pulmonary hypertension), although atrial dilatation is an increasingly recognised cause. Awareness of the poor prognosis associated with increasing TR severity has refocused the quest for effective treatments. Surgical intervention has been hindered by high in-hospital mortality (up to 10%), even in carefully selected cases, and transcatheter tricuspid valve interventions (TTVIs) have emerged as a low-risk alternative for this high-risk cohort. Increasing data demonstrate the clinical safety and efficacy of TTVIs, but uncertainties remain concerning optimal case selection and procedural timing. Herein, we review newly established techniques alongside emerging clinical and procedural outcome data.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
